[mrtesthah]

> It has not been approved nor completed normal testing trials. Otherwise it wouldn't have had to receive emergency use authorization.

That's false. The mere fact that a vaccine is EUA does not mean that it hasn't been tested. The vaccines available under EUA today have gone through exactly the same testing phases as fully FDA-approved ones. The only difference is that the phases were overlapping instead of performed serially. The link you reference already explains this.

[ScoobleDoodle]

I did not say it had no testing at all. It has gone through short term testing. But it has insufficient testing to pass the standard hurdles and thus could only be used with the Emergency Use Authorization. Which carries with it the risks of consequences being unknown. As in this case, the long term consequences. And that’s where the category of experimental unknown results lays and how the Geneva Convention on human rights applies: not being allowed to force this vaccine on people through force or coercion.

[mrtesthah]

The vaccine has now been administered to more people than any other medication in the history of humanity, with more data points collected than any other medication. There's no way that your claim that it hasn't been sufficiently tested stands up here, at all. It's a transparent lie.

And on the topic of ethics, we have more than enough data on the rate of bodily damage and death caused by the covid virus to make vaccines available to the public as soon as practically possible. Any public policy of holding back vaccines for years of small-scale testing in the face of such mass death would be tantamount to genocidal negligence.

[vetinari]

They didn't go exactly the same testing phases; the serialization doesn't work like that, you cannot replace time with parallelism (the 9 pregnant women is a suitable analogy).

So, the timeline is:

- Corminaty; currently doing phases 3 and 4; assumed end is december 2023;

- Spikewax: currently doing phases 3 and 4; assumed end is december 2022;

- Vaxzevria: currently doing phases 3 and 4; assumed end is second quarter 2022;

- Janssen: still doing phases 1/2a, 2a, 3; assumed end december 2023;